Brief: MAIA Biotechnology Reports Updates For THIO-101 Phase 2 Trial
11/07/2023 13:13
July 11 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY REPORTS UPDATES ON DISEASE CONTROL
RATES FOR
THIO-101 PHASE 2 TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER
* MAIA BIOTECHNOLOGY INC - OF FIRST 11 PATIENTS WITH
POST-BASELINE
SCANS, 9 MET DISEASE CONTROL PRIMARY ENDPOINT AT FIRST RESPONSE
ASSESSMENT
* MAIA BIOTECHNOLOGY INC - NO NEW SAFETY ANALYSIS WAS
CONDUCTED AT
THIS TIME
Source text for Eikon: ID:nBw51hdw8a
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale